June 30, 2020—Durham, NC—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, today announced that Chad Briscoe, Ph.D. has joined the organization’s leadership team as Chief Scientific Officer. In this role, Dr. Briscoe will provide scientific and regulatory oversight to BioAgilytix’s global teams with strategic guidance in line with emerging scientific developments.
Dr. Briscoe is a seasoned scientific executive with nearly 25 years of experience leading operational and scientific innovation in the bioanalytical and biomarker segments of the pharmaceutical industry. Prior to joining BioAgilytix, Dr. Briscoe was executive director of global bioanalytical science for a large contract research organization, where he was responsible for global laboratory scientific strategy including team leadership and key client relationship oversight. Today he is a recognized global expert and thought leader in areas including regulated bioanalysis, analytical instrument qualification, and biomarker analysis with immunoassays, flow cytometry, and genomics techniques. Dr. Briscoe is also a sought-after speaker at industry events such as WRIB, the Global CRO Council, Land O’ Lakes, Global Bioanalysis Consortium, APA, APS, CPSA, and ASMS, and is often requested to participate in industry forums as a collaborator and mentor.
“It is with great excitement that we welcome Chad to the BioAgilytix team,” said Jim Datin, President and Chief Executive Officer of BioAgilytix. “Not only is he an esteemed bioanalytical thought leader, but also a driven problem-solver with a long track record helping pharma and biotech innovators bring their drugs to market efficiently. His leadership will be a great asset to our customers in helping them better plan for and execute the bioanalytical aspects of their clinical trials, and in guiding our team to deliver robust but practical solutions that successfully address the ever-increasing complexities of large molecule drug development.”
“Over the course of my career, I have developed a true passion for the indispensable role of bioanalytical scientists in the drug development process – and I’m thrilled to now be able to collaborate with and guide one of the most talented, dedicated scientific teams I’ve ever had the opportunity to work with,” said Dr. Briscoe. “We’re collectively committed to helping customers bring new drugs to market faster, and it will be exciting to take on new bioanalytical challenges alongside these colleagues.”
BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle area, the Cambridge area of Massachusetts, and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e. product release testing, stability testing, etc.). BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory.
BioAgilytix’s team of highly experienced scientific and QA professionals ensures high-quality science, data integrity, and regulatory compliance through all phases of clinical development, and is a trusted partner to many of the top global pharmaceutical and biotech companies. For more information, visit www.bioagilytix.com.